secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2025-02-10T23:59:59+00:00
Accession:  0001140361-25-003639
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant Q3 loss $208.9M; cash $5.2B; launches brepocitinib Ph2 in sarcoidosis
-----------------------------------------------------------------------------

- Revenue $9.0M (-42% YoY); loss from continuing ops $208.9M vs. $5.1B income in prior year (Telavant gain).
- Cash and marketable securities $5.2B at Dec 31; plus $75M VTAMA milestone and $113M from Immunovant private placement.
- New brepocitinib Phase 2 in cutaneous sarcoidosis; topline data expected H2 2026.
- Batoclimab pivotal trial results in MG and CIDP expected by March 31, 2025; IMVT-1402 pivotal trials initiated in GD and D2T RA.
- LNP litigation vs. Moderna: summary judgment Q2/Q3 2025, jury trial Sept 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036125003639/0001140361-25-003639-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036125003639/ef20043151_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-003639

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer